Introduction
Chronic intestinal inflammation in Crohn's disease (CD) is caused by an aberrant interaction between the mucosal immune system and luminal antigens, often leading to a compromised IEC barrier, in genetically predisposed individuals1. There is an increasing appreciation for the importance of variable cellular processes in intestinal epithelial cells (IECs) that contribute to the loss of barrier capacity and the development of CD2, 3. We4-6 and others7 have shown that alterations in IEC gene expression are associated with CD, but the underlying mechanisms driving IEC barrier defects remain unresolved. Current management of CD is largely directed at aberrant immune responses while CD therapy targeting IEC barrier defects remain elusive8.
In contrast to the small intestine where Paneth cells provide additional support for epithelial barrier integrity in part by secreting antimicrobial peptides, the colonic IEC barrier is largely maintained by tight cell-to-cell connections between colonocytes and by the mucus secreted from goblet cells9. Colonocytes are also enriched with junctional proteins10 that serve as a barrier to luminal contents. Defects in the colonocyte barrier can increase paracellular permeability, which has been shown to lead to intestinal inflammation in several rodent models11, 12. Mechanisms controlling human colonocyte differentiation and survival are still understudied, especially in CD patients.
We recently reported aberrantly elevated expression of microRNA-31-5p (miR-31-5p) in colonic IECs of CD patients compared to non-inflammatory bowel disease (NIBD) controls4. miRNAs contribute to the control of various biological processes, including proliferation and differentiation13, by post-transcriptionally regulating target gene expression14. We hypothesized that miR-31-5p might contribute to the pathophysiology of CD through regulation of key genes that drive colonic IEC proliferation and differentiation. In this study, we identified and validated a novel miR-31-5p target gene, Activin Receptor-Like Kinase 1 (ACVRL1 or ALK1), in human colonic IECs. The functions of ALK1 in the colon have not previously been investigated. We examined the functional impact of ALK1 signaling on IEC biology, notably colonocyte differentiation and barrier integrity, using human primary IECs. We also examined the clinical impact of altered colonic ALK1 in patients with CD and demonstrated an association of decreased colonic ALK1 with increased risks of surgery and endoscopic relapse.
Materials and Methods

Subjects, Samples, and Clinical Information
Colonic mucosa was obtained from surgically resected colon or endoscopically taken biopsies from patients with established diagnosis of CD and NIBD healthy controls between April 2012 and November 2019. Cross-sectional clinical data was collected at the time of sampling. All samples were collected from disease-unaffected regions without macroscopic inflammation. All biopsy samples were collected from ascending colon. Additional information for surgical samples is summarized in Supplementary Table 1 . Endoscopic disease activity was evaluated by Simple Endoscopic Score for Crohn's Disease (SES-CD)15 in CD patients. Information required for scoring was retrospectively extracted from endoscopy reports. Endoscopic remission was defined as SES-CD less than 416. In patients with endoscopic remission, endoscopic disease activity was prospectively followed up to 72 weeks after sampling to examine endoscopic relapse, defined as SES-CD ≧4.
Isolation of Colonic Crypts and Primary Culture of Human Intestinal Epithelial Cells
Isolation of colonic crypts and subsequent human primary IEC culture were performed as we reported previously17, 18. In brief, colonic mucosa was incubated in the isolation buffer17, 18 for 75 minutes at room temperature. The tissue was rinsed with Phosphate Buffered Saline (PBS) and vigorously shaken by hand to release the crypts. The released crypts were placed into culture immediately or suspended in expansion medium (EM)18 containing 20% FBS and 10% dimethyl sulfoxide (DMSO) to store at -80˚C until use.
For two-dimensional (2D) culture, isolated crypts were directly spread on 48-well plates coated with collagen hydrogel17. Cells were cultured in EM with 10mM Y-27632 (Selleckchem, TX, USA) during the initial 48 hours. The medium was changed every 48 hours. Every 6 days, cells were dissociated in collagenase type IV followed by Accutase (Stemcell Technologies, BC, Canada) and the fragmented cells were passaged to a new collagen-coated plate.
In several experiments, cells were expanded in EM for 4 days and subsequently stimulated with 10 ng/ml bone morphogenetic protein (BMP) 9 (BioLegend, CA, USA) and 100 ng/ml ALK1-Fc chimera protein (R&D Systems, MN, USA), a soluble chimeric protein consisting of the extracellular part of ALK1 fused to a Fc fragment, which inhibits BMP9-ALK1 interaction and signaling19.
Epithelial Permeability Assay
Epithelial permeability was evaluated in 2D-cultured human primary IEC monolayers as we reported previously20. Primary IECs cultured on 48-well plates were passaged to 12well cell culture inserts (transparent polyethylene terephthalate membrane, membrane pore size 0.4 um, effective cell culture area 0.9 cm2; Corning, NY, USA) coated with collagen scaffolds with a gradient of cross-linking21 at a ratio of 1:1. Cells were expanded in EM for 4 days and stimulated with 10 ng/ml BMP9 and 100 ng/ml ALK1-Fc chimera protein in EM or cultured in differentiation medium (DM) for additional 2 days. In contrast to EM, DM lack exogeneous Wnt Family Member 3A (WNT3A), R-SPONDIN 3, and NOGGIN produced from L-WRN cells18 and SB202190 (Selleckchem), a selective p38 mitogen-activated protein kinase inhibitor. The resistance between the upper and lower surfaces of IEC monolayers was measured before (Day 4) and after 2 days of stimulation (Day 6) using an EVOM2 epithelial Volt/Ohm meter (World Precision Instruments, FL, USA). The resistance of IEC monolayers was corrected by subtracting the resistance of scaffolds without cells and normalized by multiplying the effective scaffold surface area to provide a trans-epithelial electrical resistance (TEER) in the unit of Ω cm2. Changes in TEER between Day4 and Day6 were evaluated by calculating delta TEER% as following: ΔTEER% =100-[{(TEERDay4-TEERDay6)/TEERDay4} x 100]20.
3'UTR Reporter Assay and Site-directed Mutagenesis
Plasmid DNA was extracted from a miRNA 3'UTR target clone for ALK1 (HmiT022834-MT06, GeneCopoeia, MD, USA) using Qiagen Plasmid Midi Kit (Qiagen, MD, USA). This plasmid DNA was then transfected in HEK293T cells with or without miRNA mimics, double-stranded oligonucleotides designed to mimic the function of endogenous mature miRNAs, for hsa-miR-31-5p, hsa-miR-122a-5p, or hsa-miR-215-5p, or negative control mimics (Dharmacon, CO, USA). Cells transfected with plasmid DNA in the absence of miRNA mimics were defined as mock. For mutagenesis assays, putative miR-31-5p binding sequences were deleted in the plasmid DNA using PrimeSTAR Mutagenesis Basal Kit (TaKaRa Bio, CA, USA) according to the manufacturer's instructions. Successful deletions were checked by Sanger DNA sequencing (Eurofins Genomics) and subsequently analyzed with Sequencher 5.4.6 (Gene Codes). Dual luciferase reporter assays were performed on Dual Luciferase Reporter Assay System (Promega, WI, USA) using the Luc-Pair Duo-Luciferase HS Assay Kit (GeneCopoeia) according to the manufacturer's instructions.
5-Ethynyl-2-deoxyuridine assay
The 5-ethynyl-2-deoxyuridine (EdU)-based staining was performed on 2D-cultured primary IECs. Cells were sub-cultured from 48-well plates to 96-well plates at a ratio of 1:3, expanded in EM for 4 days followed by additional 2 days in EM with or without 10 ng/ml BMP9 and 100 ng/ml ALK1-Fc chimera protein or in DM. Cells were incubated with 10mM EdU for 3 hours at 37˚C. DNA-incorporated EdU was detected by Sulfo-Cyanine5azide (Lumiprobe, MD, USA) through a copper-catalyzed covalent reaction between an azide and alkyne22. Images were captured using a Nikon Eclipse TE2000-U inverted microscope (Nikon, Tokyo, Japan) and processed using NIS-Elements AR version 3.2 software. The EdU fluorescence area was measured by ImageJ software and normalized by the total cell area occupied by the Hoechst 33342 fluorescence as we described previously18.
Statistical analysis
All numerical data in the figures are expressed as means ± standard deviation (SD) or standard error of the mean (SEM Spearman's correlation coefficient was used for evaluating correlations between two numerical variables. Correlations between two categorical variables were evaluated by chi-squared test with Cramer's V to measure the strength of correlations. P-values less than 0.05 were considered significant. The Kaplan-Meier method was used to generate survival curves and differences between two groups were evaluated by log-rank test. The GraphPad Prism version 8.0 software (GraphPad Software, CA, USA) and R software version 3.5.2 were used for these data analyses. A binomial logistic regression analysis was also performed using R software.
Ethical statement
The study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice. The study protocol was approved by the institutional review board at University of North Carolina at Chapel Hill (approval number: 19-0819 and 17-0236). All participants provided written informed consent prior to inclusion in the study. All participants are identified by number and not by name or any protected health information.
Results
ALK1 is a putative target of miR-31-5p in human colonic epithelial cells
We previously generated and studied the expression profiles of mRNAs6 and miRNAs4 in the uninflamed colonic mucosa of 21 adult CD patients and 11 NIBD controls revealing a unique subset of CD patients with especially high miR-31-5p expression23. Predicted miR-31-5p target genes (n=27) were significantly enriched among the genes downregulated in this group of "high-miR-31-5p" CD patients compared to NIBD controls4 (Supplementary Table 2 ). Correlation analysis in the high-miR-31-5p CD patients revealed that 4 of these genes were significantly inversely correlated with miR-31 ( Figure  1A) . The strongest two of these were E2F Transcription Factor 2 (E2F2) and Activin Receptor-Like Kinase 1 (ALK1) (r = -0.92 and -0.90; p<0.001 and p<0.001, respectively). We next examined the association of miR-31-5p with E2F2 and ALK1 specifically in colonic IECs isolated from CD patients and NIBD controls by qPCR ( Figure 1B) , which revealed a significant negative correlation between miR-31-5p and ALK1 but not E2F2 (ALK1, p=0.019; E2F2, p=0.982, Jonckheere-Terpstra test). Relative ALK1 protein expression was significantly inversely correlated with miR-31-5p expression (r = -0.59, p<0.01) and was remarkably decreased in the colonic mucosa of CD patients with higher miR-31-5p expression compared to NIBD controls ( Figure 1C ). This suggests that ALK1 is a putative target of miR-31-5p in human colonic IECs.
miR-31-5p directly suppress ALK1 expression through binding to the 3'UTR
To test the direct association between ALK1 mRNA and miR-31-5p, we performed a 3'UTR reporter assay in HEK293T cells using synthesized miRNA and negative control mimics (Figure 2A) . The mimics for miR-122a-5p and miR-215-5p, which do not have specific binding sites in the 3'UTR of ALK1 mRNA, were used as negative controls. As we expected, miR-31-5p but not the other two miRNA mimics decreased luciferase activity compared to the mock and negative control mimic, suggesting the direct regulation of ALK1 by miR-31-5p. To further demonstrate the specific regulation of ALK1 by miR-31-5p through binding to the 3'UTR, we deleted the predicted miR-31-5p binding sequences in the reporter plasmid by site-directed mutagenesis (Supplementary Figure  1) and performed a reporter assay with miR-31-5p and negative control mimics ( Figure  2B) . The reduction in luciferase activity by exogeneous miR-31-5p mimic disappeared in the cells transfected with the mutated plasmid that does not have the intact miR-31-5p binding sequences. These results demonstrated the direct regulation of ALK1 mRNA by miR-31-5p through binding to the 3'UTR.
BMP9-ALK1 signaling restricts the stemness of human colonic IECs
ALK1 is a type 1 receptor for transforming growth factor (TGF)-beta signaling molecules24 that specifically binds to extra-enteric ligands BMP9 and BMP1025. Although ALK1 is known to be expressed in human colonic IECs26, the role of ALK1-related signaling in IEC biology remains unknown. To investigate the impact of decreased ALK1 expression in the colonic IECs of CD patients, we first examined the effect of BMP9 treatment on IEC proliferation ex vivo using NIBD patient-derived colonic IEC monolayers. We found a significantly decreased EdU incorporation in BMP9-stimulated IECs compared to nonstimulated cells (Figure 3A) . BMP9-induced reduction of EdU incorporation was recovered by sequestrating BMP9 with ALK1-Fc chimera protein, demonstrating the effect of BMP9 in restricting IEC proliferation. We also examined the effect of BMP9 on the expression of IEC proliferation-and stemness-related genes (Figure 3B) . Consistent with the results of the EdU assay, the expression of proliferation-related genes, including MKI67 and PCNA as well as stemness-related genes LGR5, OLFM4, and ASCL2, was significantly decreased in BMP9-stimulated cells. BMP9-induced reduction of expression levels of these genes was recovered by the addition of ALK1-Fc chimera protein.
We hypothesized that colonic IECs of CD patients would maintain higher stemness than those of NIBD controls due to decreased ALK1 expression. To test this hypothesis, we compared proliferation-and stemness-related gene expression in the isolated colonic IECs between NIBD and CD patients (Figure 4A) . As expected, CD patient-derived IECs exhibited significantly higher expression of LGR5 and OLFM4, and a trend toward higher levels of MKI67, PCNA, and ASCL2, than those from NIBD controls. Increased OLFM4 protein expression was confirmed by immunohistochemistry in the colonic crypts of CD patients (Figure 4B) . Taken together, these data suggest a role for BMP9-ALK1 signaling in restricting the stemness of human colonic IECs.
BMP9-ALK1 signaling drives colonic epithelial cell differentiation towards colonocytes
To define the impact of ALK1 signaling on IEC differentiation, we determined the expression of representative IEC-lineage specific genes10, 27, such as CA1 (colonocyte), MUC2 (goblet cell), CHGA (enteroendocrine cell), DEFA5 (Paneth cell), and DCLK1 (tuft cell), in NIBD patient-derived colonic IEC monolayers in the presence or absence of BMP9 stimulation. Treatment with BMP9 significantly upregulated the expression of CA1 and other colonocyte markers10, such as CEACAM1 and GUCA2A (Figure 5A) , suggesting a potential impact of BMP9-ALK1 signaling on colonocyte differentiation. BMP9-mediated upregulation of CA1 expression was confirmed at the protein level ( Figure 5B) . The pro-colonocytic effect of BMP9 was significantly mitigated by ALK1-Fc chimera protein (Figure 5A) . These data demonstrate that BMP9-ALK1 signaling preferentially drives colonic IEC differentiation towards colonocytes.
We also hypothesized that decreased ALK1 expression in CD patients would result in decreased colonocyte marker expression compared to NIBD controls. To test this hypothesis, we compared expression of colonocyte markers in isolated colonic IECs between NIBD and CD patients (Figure 6A) . CD patient-derived IECs showed significantly lower CA1, CEACAM1, and GUCA2A expression than IECs from NIBD controls. Reduced CA1 protein expression was also confirmed in the colonic mucosa of CD patients (Figure 6B and 6C) . Taken together, these data demonstrate for the first time the role of BMP9-ALK1 signaling in colonocyte differentiation.
BMP9-ALK1 signaling does not affect migration of human colonic IECs
IECs migrate to wound sites and cover the denuded surface, an important step in the wound healing process28. We investigated the effect of BMP9-ALK1 signaling on wound healing using NIBD patient-derived colonic IEC monolayers. We measured how much of a wounded area was covered by migrated IECs within 24 hours after BMP9 stimulation (Supplementary Figure 2) . The presence of BMP9 did not affect the amount of covered area at either 8 and 24 hours after stimulation. These results suggest that BMP9-ALK1 signaling has little or no impact on cell migration.
BMP9-ALK1 signaling enhances human colonic IEC barrier integrity
Because colonocytes play a key role in barrier function, we hypothesized that ALK1 signaling could influence barrier integrity. To test this hypothesis, we generated IEC monolayers on transwells using NIBD patient-derived colonic crypts, which were cultured in the presence or absence of BMP9 (Figure 7A) . BMP9 stimulation significantly enhanced IEC barrier integrity as shown by increased ΔTEER% (Figure 7B) . This BMP9induced increase in ΔTEER% was abrogated by ALK1-Fc chimera protein. These results suggest that increased BMP9-ALK1 signaling enhances human colonic IEC barrier integrity.
Decreased colonic ALK1 is associated with increased risk of surgery and endoscopic relapse in CD patients.
We hypothesized that impaired ALK1 signaling, due in part to the associated defects in colonocyte maturation and barrier integrity, would be associated with poor clinical outcomes in CD. To study this, we examined ALK1 expression in the colonic mucosa of a new, independent cohort of 28 CD patients and 10 NIBD controls using endoscopicallycollected biopsy samples (Figure 8A) . CD patients showed lower colonic ALK1 expression than NIBD controls as a whole, but a subset of CD patients showed markedly lower ALK1 expression (Low-ALK1 CD subset) than the other CD patients (Hi-ALK1 CD subset). Therefore, we compared the clinical characteristics between these ALK1-based CD subsets (Table 1) . Interestingly, Low-ALK1 patients were more likely to experience bowel resections than Hi-ALK1 patients (93.3% vs. 53.8%, p=0.029). We examined the potential effect of surgery on colonic ALK1 expression among 5 matched CD patients by prospectively determining ALK1 expression after bowel resections. Within the median 6month follow-up period, there was no significant change in the colonic ALK1 expression (Supplementary Figure 3A) . To evaluate the net impact of colonic ALK1 expression on the risk of surgery in CD patients, we conducted a multivariate analysis. In addition to well-accepted risk factors29 that include young age (under 40 years) at diagnosis, extensive disease (disease location30), use of corticosteroids to control the index flare, and perianal disease at diagnosis, we used membership in the colonic ALK1-based CD subset and use of anti-TNF alpha agents as additional independent variables that could impact the outcome (risk of surgery). Among these potential risk factors, young age at diagnosis was removed from subsequent analysis because of its significant correlation with membership in the colonic ALK1-based CD subset ( Supplementary Table 3 and Supplementary Figure 3B) . A binomial logistic regression analysis revealed that having a Low-ALK1 CD subtype is an independent risk factor for surgical resection in CD patients ( Table 2 ). Next, we prospectively tracked endoscopic disease activity in 21 patients who were in remission at the time of sample collection. Within a 72-week observational period, 5 of 12 Low-ALK1 and 0 of 9 Hi-ALK1 CD patients experienced endoscopic relapse. A significantly higher risk of endoscopic relapse was demonstrated in patients in the Low-ALK1 CD subset compared to the Hi-ALK1 subset (p<0.05, Log-rank test) ( Figure 8B) . All patients showed exacerbated inflammation in the colon except for one patient with endoscopic relapse only in ileum. Taken together, these data suggest that decreased colonic ALK1 expression is associated with increased risk of surgery and endoscopic relapse in patients with CD.
Discussion
ALK1 is a transmembrane serine/threonine receptor kinase that belongs to the TGF-beta receptor family. In contrast to the broad ligand-binding specificity of other type 1 receptors for TGF-beta signaling molecules (ALK2-7), ALK1 specifically binds to BMP9 and BMP10 secreted from liver31 and heart32, respectively. ALK1 is expressed in endothelial cells and plays a crucial role in the development of direct connections between arteries and veins33.
Defects in ALK1 signaling lead to arteriovenous malformations and cause hereditary hemorrhagic telangiectasia (HHT), which is characterized by mucocutaneous telangiectasia and gastrointestinal hemorrhage, in genetically predisposed patients34. Recent tissue proteome analyses revealed ALK1 expression in human IECs as well as endothelial cells in small and large intestines26. However, the role of ALK1 signaling in colonic IEC homeostasis and the clinical impact of attenuated ALK1 signaling in CD have never been investigated. In this manuscript, we identified ALK1 as a target of miR-31-5p4, 5. We demonstrated a dramatic reduction of ALK1 in the colonic IECs of CD patients and showed that ALK1 controls colonocyte differentiation and intestinal epithelial barrier capacity.
BMP4 signaling through ALK3 was previously reported to restrict the stemness of murine Lgr5-positive intestinal stem cells35. Although ALK1 and ALK3 similarly affect downstream Smad signaling pathways to regulate gene expression24, the role of ALK1-related signaling on IEC stemness remained unknown. Therefore, we examined the impact of ALK1 signaling on the stemness of human colonic IECs ex vivo using primary-cultured IECs. BMP9-ALK1 signaling reduced the expression of stemness-related genes including LGR5, restricted proliferation, and directed the fate of human IEC differentiation toward colonocytes. These data clearly demonstrated the effect of BMP9-ALK1 signaling in restricting human IEC stemness, similar to BMP4-ALK3 signaling. Decreased ALK1 expression was associated with increased stemness-related marker expression and decreased colonocyte differentiation in the colonic IECs of CD patients compared to NIBD controls. We also demonstrated that increased BMP9-ALK1 signaling enhanced IEC barrier integrity by decreasing paracellular permeability. Although the mechanism of decreased paracellular permeability in BMP9-stimulated IECs needs further investigation, the effect of BMP9-ALK1 signaling in colonocyte differentiation and the role of colonocytes in colonic barrier integrity9 implies that activated ALK1 signaling might enhance barrier integrity by driving colonocyte differentiation and maturation.
Based on these data, we hypothesized that attenuated ALK1 signaling might result in a poor clinical outcome in CD patients due to disrupted colonic barrier function. Association analyses with clinical outcomes revealed that decreased colonic ALK1 expression is an independent risk factor for surgery and is associated with an increased risk of endoscopic relapse in the future. Despite the demonstrated role of ALK1 signaling in epithelial barrier function, loss-of-function mutations in ALK1 do not result in spontaneous intestinal inflammation in patients with HHT36. This fact in consistent with previous lines of evidence from rodents37-39 and asymptomatic first-degree relatives of CD patients2 suggesting that increased epithelial permeability is necessary but not sufficient for the development of intestinal inflammation and requires another trigger for disease manifestation in CD40. Nonetheless, our data suggested that disrupted ALK1 signaling might be one of the disease-modifying factors that contribute to the heterogeneity in clinical outcomes among CD patients. Finding markers predicting the natural course of CD is the holy grail of medical researchers in the field41. Our findings suggest that colonic ALK1 expression levels may help identify these high-risk patients who may require early intensified therapeutic intervention, perhaps staving off a poor clinical outcome. Intriguingly, we found a significant correlation between colonic ALK1-based CD subset and young age at diagnosis as independent variables for the regression analysis. The younger age at diagnosis in Low-ALK1 CD subset compared to Hi-ALK1 subset might partially explain the unknown mechanism why young age at diagnosis can be a risk factor for the disabling course in CD patients. Our findings also show a potential use of ALK1 as a novel target of medical treatment in CD. An increasing number of drugs targeting mucosal immune cells are currently available in the treatment for CD; however, there is no established treatment targeting IEC defects8. A small biologic potentiator of colonic ALK1 expression could be a first-ever treatment targeting IECs in CD.
There are several limitations in our study. Firstly, we did not investigate the impact of decreased E2F2, another candidate target of miR-31-5p, in CD patients. E2F2 is a transcriptional factor that plays an important role in regulating cell proliferation42, 43. Our data suggested that miR-31-5p regulation of E2F2 expression does not occur in colonic IECs of CD patients. However, increased miR-31-5p was also found in CD14 negative resident macrophages and B lymphocytes in the colon of CD patients4. Future investigation will be required to understand the potential impact of decreased E2F2 expression in these non-epithelial cells. Secondly, we did not examine the impact of ALK1 signaling on IECs from the small intestine. We previously reported an upregulation of miR-31-5p in the ileal tissue of CD patients compared to NIBD controls4. Given that ALK1 is expressed in the IECs of small intestine as well as colon26, investigation of the role of ALK1 signaling in small intestinal IECs will be informative. Thirdly, we did not investigate the impact of decreased ALK1 on vascular development in the intestine. ALK1 has a wellaccepted role in vascular development, thus increased miR-31-5p might affect vascular formation in the intestine of CD patients. Finally, we did not examine the effect of BMP10, another ligand for ALK1, on ALK1 signaling in IECs. Both BMP9 and BMP10 can bind to ALK1 with high affinity in vivo. However, in contrast to BMP9 which circulates in a biologically active form31, there remains an active debate about the latency of BMP1044. Therefore, we selected BMP9 for our ex vivo experiments. Nevertheless, distinct roles of these two BMPs were previously reported in tumor growth, and thus further investigation of the impact of BMP10 on IEC biology will be necessary in the future.
To our knowledge, this study is the first to investigate the mechanism of CD using human primary IEC monolayers ex vivo. Our innovative technologies, such as cell proliferation, wound healing, and epithelial permeability assays in 2D-cultured primary IECs, will promote further research to understand mechanisms of IBD and develop novel drugs targeting IECs in the future. . 8. (A) The impact of colonic ALK1 expression on clinical outcome. ALK1 expression was quantified in colonic biopsy samples obtained from NIBD controls (N=10) and CD patients (N=28) by qPCR. ALK1 expression was normalized to GAPDH. ***P<0.001. P-value was determined by Mann-Whitney test. (B) Kaplan-Meier survival analysis to evaluate the impact of colonic ALK1 expression on the endoscopic relapse in patients with CD (N=12 for Low-ALK1 and 9 for Hi-ALK1 CD subgroups). P-value determined by Log-rank test. 
